Straits Times Index
2,998.77+2.85(+0.10%)S&P 500
3,851.85+52.94(+1.39%)Dow
31,188.38+257.86(+0.83%)
Geron Corporation (GERN)
1.7600 +0.02 (1.15%)
After hours: 6:39PM EST
| Previous close | 1.7700 |
| Open | 1.7712 |
| Bid | 1.7200 x 27000 |
| Ask | 1.7600 x 4000 |
| Day's range | 1.7200 - 1.8068 |
| 52-week range | 0.7500 - 2.4000 |
| Volume | 2,269,501 |
| Avg. volume | 2,364,438 |
| Market cap | 540.221M |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET.
- Business Wire
Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).
- Business Wire
Geron Announces Fifty Percent Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS). Data from the IMerge Phase 2 were recently presented at the American Society of Hematology Annual Meeting and support the ongoing Phase 3.
